Get the Stockscreener App
0.1906
11.59%
0.0198
Valion Bio Inc stock is traded at $0.1906, with a volume of 169.19M.
It is up +11.59% in the last 24 hours and down -59.38% over the past month.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
See More
Previous Close:
$0.1708
Open:
$0.162
24h Volume:
169.19M
Relative Volume:
31.04
Market Cap:
$791.23K
Revenue:
$232.00K
Net Income/Loss:
$-12.13M
P/E Ratio:
-0.0213
EPS:
-8.9454
Net Cash Flow:
$-10.29M
1W Performance:
-33.22%
1M Performance:
-59.38%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.1602
$0.2926
1-Week Range:
$0.1594
$1.30
52-Week Range:
$0.1594
$1.30
Valion Bio Inc Stock (VBIO) Company Profile
Name
Valion Bio Inc
Sector
Industry
Phone
(888)276-6888
Address
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.86 | 2.83B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.89 | 388.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.88 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.45 | 348.74M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
48.03 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc Stock (VBIO) Latest News
Valion Bio (VBIO) investor group reports 1.74M shares, capped at 9.9% stake - Stock Titan
Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning - Stock Titan
Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary - TradingView
Entolimod Could Receive Its First National Registration in Ukraine - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Valion Bio, Inc. (VBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Valion Bio Inc. (VBIO) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall - Yahoo Finance
Valion Bio begins safety study for radiation injury drug - Investing.com
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Valion Bio Plans Mouse Study After Lethal Radiation Exposure - Stock Titan
Valion Bio, Inc. (OTC: VBIO) investors file 13D/A and outline $9M preferred stock plan - Stock Titan
Valion Bio, Inc.Common stock (Nasdaq:VBIO) Stock Quote - FinancialContent
Insiders Who Sold Valion Bio Missed Out On 19% Stock Increase - webull.com
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - TradingView
3i, LP Pushes for Changes at Valion Bio with 9.9% Stake - TradingView
Valion Bio Inc (NASDAQ: VBIO) Share Price, VBIO Stock News, VBIO Share Price & Updates - Kalkine
Murchinson Ltd. Acquires 440,242 Shares in Valion Bio Inc. - GuruFocus
Ukraine could issue an Entolimod decision in as few as 45–60 days - Stock Titan
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway - Morningstar
Planned cancer trial will test whether Entolimod protects marrow - Stock Titan
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial By Investing.com - Investing.com Canada
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial - Investing.com
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market - PR Newswire
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
Form S-1 Valion Bio Inc For: 17 July By Investing.com - Investing.com Nigeria
Valion Bio Offering Up to 29.4M Shrs and Up to 29.4M Common Warrants - Moomoo
IPO Databook: Valion Bio (VBIO US)Jul 2026 - Smartkarma
Form S-1 Valion Bio Inc For: 17 July - Investing.com India
Form DEF 14A Valion Bio Inc For: 17 July By Investing.com - Investing.com Canada
Valion Bio (OTC: VBIO) asks holders to OK 1-for-5 to 1-for-50 reverse split - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Valion Bio, Inc.: Shareholders Board Members Managers and Company Profile | US8887053085 - marketscreener.com
Valion Bio advances Entolimod platform and manufacturing scale-up - The Globe and Mail
Valion Bio, Inc. Expands Manufacturing Capacity and Pursues Government and International Preparedness Opportunities - marketscreener.com
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - Fidelity Investments
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Valion Bio Reports Entolimod Scale-Up Equal to ~1.3M Potential Human Doses - Stock Titan
Valion Bio (VIBO) Emerging Growth Conference 89 Summary - Quartr
Enterprise value to EBITDA forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Form PRE 14A Valion Bio Inc For: 7 July By Investing.com - Investing.com Nigeria
[PRE 14A] Valion Bio, Inc. Preliminary Proxy Statement - Stock Titan
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - AOL.com
Valion Bio (VIBO) Proxy filing Summary - Quartr
VBIOValion Bio Inc Dividends - Finviz
Price to book forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
Enterprise value to EBIT forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Price to earnings forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Valion Bio’s Entolimod gets protocol design for radiation syndrome study - Investing.com
Valion Bio Inc Stock (VBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):